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Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection. This encephalopathy 
is characterized by coma and is thought to result from mechanical microvessel obstruction and an 
excessive activation of immune cells leading to pathological inflammation and blood-brain barrier 
alterations. IL-22 contributes to both chronic inflammatory and infectious diseases, and may have 
protective or pathogenic effects, depending on the tissue and disease state. We evaluated whether 
polymorphisms (n = 46) of IL22 and IL22RA2 were associated with CM in children from Nigeria and 
Mali. Two SNPs of IL22, rs1012356 (P = 0.016, OR = 2.12) and rs2227476 (P = 0.007, OR = 2.08) were 
independently associated with CM in a sample of 115 Nigerian children with CM and 160 controls. The 
association with rs2227476 (P = 0.01) was replicated in 240 nuclear families with one affected child 
from Mali. SNP rs2227473, in linkage disequilibrium with rs2227476, was also associated with CM 
in the combined cohort for these two populations, (P = 0.004, OR = 1.55). SNP rs2227473 is located 
within a putative binding site for the aryl hydrocarbon receptor, a master regulator of IL-22 production. 
Individuals carrying the aggravating T allele of rs2227473 produced significantly more IL-22 than those 
without this allele. Overall, these findings suggest that IL-22 is involved in the pathogenesis of CM.
Malaria is endemic to more than 90 countries and continues to be a major global health challenge. In 2015, there 
were an estimated 214 million clinical cases of malaria and 438000 deaths. Most deaths occur among children 
under the age of five years living in Sub-Saharan Africa. Only 5% of people infected with P. falciparum develop 
severe malaria, and disease outcome is influenced by host genetic factors. Infection with P. falciparum may result 
in severe clinical diseases, such as cerebral malaria, severe malarial anemia, respiratory distress and hemoglobi-
nuria. Cerebral malaria is one of the most severe forms of the disease and is characterized by encephalopathy with 
loss of consciousness. The sequestration of parasitized red blood cells in the small capillaries of the brain leads to 
mechanical obstruction, hypoxia, the activation of local immune cells and local inflammation. Independent stud-
ies have also suggested functional impairment of the blood-brain barrier (BBB) in the pathophysiology of CM1–3.
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IL-22, a member of the IL-10 cytokine family, induces the early recruitment of immune cells, stimulates the 
local production of antimicrobial molecules, and promotes the repair of damaged epithelia and the “anti-LPS” 
response4,5. IL-22 acts on non-hematopoietic cells such as epithelia, hepatocytes, and pancreatic cells, and is 
produced by many different types of lymphocytes of the innate and adaptive immune systems5,6, including CD4 
T cells, such as Th17 and Th22 cells, γ δ T cells, natural killer (NK) cells, lymphoid tissue inducer (LTi) cells, and 
LTi- like cells5–7. The heterodimeric receptor for IL-22, composed of IL-22R1 and IL-10R2 chains, is expressed 
exclusively on non-hematopoietic cells. IL-10R2 is ubiquitously expressed8, whereas IL-22R1 expression is limited 
to tissues such as the skin, liver, lung, kidney, pancreas, and the surface of human BBB endothelial cells9. There 
is also a secreted IL-22-binding receptor, the IL-22 binding protein (IL-22BP), encoded by an independent gene 
(IL22RA2). IL-22BP lacks the intracellular and transmembrane domains of the IL-22R10,11 but has a high affinity 
for IL-22. IL-22BP therefore competes strongly with IL-22R for IL-22 binding.
The role of IL-22 in inflammatory and infectious diseases depends on the tissue and the disease. IL-22 protects 
against acute hepatitis5,12 and stimulates tissue regeneration in experimental models of liver disease13. It protects 
against liver fibrosis and cirrhosis in humans with chronic liver infections14 and has also been associated with pro-
tection against human Kala Azar15. By contrast, IL-22 plays a pathogenic role in multiple sclerosis by promoting 
leukocyte infiltration in the brain9 and contributes to the pathogenesis of West Nile encephalitis by facilitating the 
infiltration of the CNS with neutrophils following infection16. IL-22 has also been implicated in Guillain-Barré 
Syndrome, an acute autoimmune-mediated inflammatory demyelinating disease17.
We hypothesized that IL-22 might play a role in the response to Plasmodium falciparum infection, given the 
presence of the IL-22R complex at the BBB and the implication of IL-22 in the early immune response to patho-
gens. We report here genetic evidence for the involvement of IL-22 in cerebral malaria in children.
Results
The IL22 variants rs1012356 and rs2227476 are associated with childhood cerebral malaria. 
We selected 46 TagSNPs within the IL22 and IL22RA2 genes and a 5 kb region upstream and downstream from 
these two genes (Table 1). These SNPs are representative of the correlation bins (r2 = 0.8) established with the 
1000 Genomes YRI database. We successfully genotyped 40 polymorphisms in the Nigerian population, which 
consisted of 115 children with cerebral malaria and 160 community controls (stage 1 in Fig. 1). Univariate analy-
sis showed no significant association between CM and the IL22RA2 polymorphisms tested. The analysis revealed 
a significant association with disease for IL22 SNP rs1012356 (bin II) and IL22 SNP rs2227476 (bin III) (P < 0.05) 
(Table 2). The most significant association was observed for SNP rs2227476 (P = 0.018) [OR = 1.85 (1.11–3.08)]. 
The T allele of rs2227476 was more frequent among cases (32.8%) than controls (23.9%), (P = 0.028). We iden-
tified a trend towards association with CM for two other polymorphisms from two other bins: rs1179251 (bin I) 
(P = 0.057; OR = 1.61) and rs4913285 (bin IV) (P = 0.056; OR = 1.74) (Table 2). Multivariate analysis on SNPs 
rs1179251, rs1012356, rs2227476, and rs4913285 showed that rs1012356 (P = 0.016; OR = 2.12), and rs2227476 
(P = 0.007; OR = 2.08) were independently associated with CM (Table 2). The other SNPs were not significantly 
associated with CM. SNPs rs1012356 and rs2227476 are located within the intron and the 5′ region of the IL22 
gene, respectively.
We then evaluated these two SNPs associated with CM in the Nigerian cohort (stage 2 in Fig. 1) in a second 
cohort consisting of 240 nuclear families from Mali. The association of SNP rs2227476 (2-tailed test; P = 0.008) 
with CM was replicated. The T allele was identified as the risk allele, as in the Nigerian sample (Table 3). Using a 
case-pseudo control data set and conditional logistic regression, we obtained an estimated OR of 1.56 (1.09–2.17). 
This association remained significant after permutation testing (P = 0.01). We identified a trend towards associa-
tion with CM for the rs1012356 polymorphism (P = 0.06). The rs1012356 SNP was not retained in the model in a 
multivariate analysis including both SNPs.
SNP rs2227473, which is in linkage disequilibrium with rs2227476, is also associated with 
CM in both populations. We then investigated the possible association of additional polymorphisms in 
linkage disequilibrium with rs2227476 with CM in the Malian sample. We selected all SNPs correlated with 
rs2227476 (r2 > 0.6) in an analysis of the 1000 Genomes YRI database and located within 1 Mb on either side of 
the rs2227476 polymorphism. We identified 14 SNPs clustered together in 7.3 kb of the 5′ region of IL22.
We genotyped the Malian nuclear families for these SNPs (stage 3 in Fig. 1). We excluded one SNP from the 
Sequenom Plex for genotyping because it did not pass the quality control filter. We found that rs2227473 was 
also associated with CM in the Malian cohort (2-tailed test; P = 0.007). The minor T allele, with a frequency of 
0.25, was overrepresented in the children with CM (112 rather than the 94.2 expected in the absence of associa-
tion), OR = 1.64 (1.15–2.35). We checked that rs2227473 was also in linkage disequilibrium (LD) with rs2227476 
(r2 = 0.5) in the Malian cohort.
We validated the association of rs2227473 with CM in the case-control cohort from Nigeria, (stage 4 in Fig. 1). 
This variant was associated with disease in Nigeria (one-tailed test; P = 0.038), OR = 1.56 (1.04–2.55), the fre-
quency of the T allele being higher among cases (0.32) than controls (0.25). The risk allele (T) was identical in the 
two cohorts from Nigeria and Mali.
Finally, we analyzed the association of rs2227476 and rs2227473 with CM for the entire study population, 
by combining the case-control and familial data. Univariate analysis indicated that both SNPs were associated 
with CM (P ≤ 0.05) (Table 4). In multivariate binary regression analysis, the rs2227473 polymorphism remained 
significantly associated with CM (P = 0.004), with an estimated OR of 1.54 (1.15–2.07), whereas rs2227476 was 
not significantly associated with the disease in the combined sample set. These results confirm the association 
between IL22 SNPs and the development of CM in both Nigerian and Malian children.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:41636 | DOI: 10.1038/srep41636
The rs2227476 and rs2227473 IL22 polymorphisms may both have functional effects. We car-
ried out an in silico search for transcription factor binding sites encompassing rs2227476 and rs2227473 in the 
5′ region of IL22. We found that GATA could potentially bind to DNA only in subjects carrying the T allele for 
rs2227476. We also found that rs2227473 was located within a putative binding site for the aryl-hydrocarbon 
Gene (chr) TagSNP Position
Minor 
Allele
Major 
Allele MAF
Call 
rate % HWp
IL22 rs1179246 68640583 A C 0.39 98.2 0.58
(12) rs2227507 68642646 C T 0.06 97.4 0.54
rs1179249 68644780 T G 0.14 98.7 0.1
rs2227495 68644726 G A 0.14 96.9 0.77
rs2227485 68647713 A G 0.49 96.1 0.08
rs2227476 68648816 T A 0.32 95 0.1
rs11177135 68649606 A G 0.11 91 0.08
rs17105141 68650108 G A 0.18 98.2 0.46
rs58254691 68640611 T G 0.08 92 1
rs1182844 68641532 A T 0.31 94 0.09
rs2227505 68643267 T C 0.06 99.7 0.1
rs1012356 68644618 T A 0.47 98.7 0.2
rs1179251 68645051 G C 0.45 98.5 0.64
rs2046068 68645975 G T 0.12 97.7 0.49
rs2227491 68646521 T C 0.41 99 0.46
rs7139027 68649389 T C 0.14 97.1 0.42
rs115479956* 68649678 G A 0.05 / /
rs7302661 68651459 T C 0.08 98.5 0.29
rs4913285 68652532 T C 0.15 97 0.2
IL22RA2 rs28362176 137465084 A G 0.05 93.2 0.26
(6) rs79938603 137461160 A G 0.08 95.3 0.39
rs28385776 137473682 A G 0.05 99.7 0.47
rs85462 137463154 G C 0.08 97.9 0.09
rs79745323* 137463396 A G 0.10 / /
rs17066102* 137464837 C G 0.25 / /
rs10484798 137470756 C T 0.30 97.9 0.82
rs7774349 137475858 T C 0.05 100
rs202568 137471184 T C 0.11 98.2 0.29
rs28385776 137473682 A G 0.05 99.7 0.47
rs28385767 137481894 A G 0.24 99.5 0.2
rs1040622 137483258 C T 0.07 98.7 0.72
rs73560046 137493433 T C 0.1 99 1
rs9494683 137492101 T C 0.16 95.6 0.29
rs742931 137495707 G T 0.23 96.4 0.72
rs202563 137461492 A G 0.41 98.5 0.81
rs156751 137463294 T C 0.05 99.5 0.48
rs11154911 137466364 T C 0.05 99.5 0.48
rs114513054 137467551 G C 0.08 99.2 0.86
rs28362171* 137469118 C G 0.07 / /
rs7750867 137470186 T C 0.07 97.1 0.43
rs28362169 137471111 T C 0.08 99.5 0.92
rs74413263 137482668 G A 0.06 91.9 0.44
rs73560035* 137483523 T C 0.05 / /
rs113837410* 137487743 C T 0.08 / /
rs28362847 137492804 A G 0.33 99.5 0.89
rs6570137 137498645 T C 0.1 97.1 0.64
Table 1. List of the 46 TagSNPs included in the discovery study. *These SNPs were excluded due to a low call 
rate. aPosition according to human hg19 genome coordinates. bMAF (minor allele frequency) was estimated 
for the YRI population according to 1000 Genomes project data. cThe call rate indicates the efficiency of 
genotyping. dHWp (Hardy-Weinberg p value) estimated with Genepop.
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receptor (AhR-ARNT) complex transcription factor. This complex is a potent inducer of IL22 expression. 
These analyses suggest that rs2227476 and rs2227473, located in the promoter region of IL22, can modify IL22 
expression.
Discussion
We identified susceptibility variants of the IL22 gene associated with childhood CM, in two independent African 
populations. The association study was performed in two stages, with an initial case-control study population in 
Figure 1. Scheme of the study design. The association study was performed in a Nigerian case-control cohort, 
with subsequent replication in a family-based Malian population. Two SNPs located in the promoter region of 
IL22 were associated with CM in both populations.
Bin SNP
Minor 
Allele MAFa Genotypes Controls % Cases % OR 95% CI Pb
Univariate analysis
I rs1179251 G 0.42 GG, CC 47.8 59.6 1.61 1.02–2.64 0.057
II rs1012356 T 0.47 TT 19 31.2 1.93 1.10–3.41 0.022
III rs2227476 T 0.24 TT, TA 38.2 53.3 1.85 1.11–3.08 0.018
IV rs4913285 T 0.10 TC, TT 18.9 28.8 1.74 1.02.3.09 0.056
Multivariate analysis
II rs1012356 T 0.47 TT 2.12 1.1–3.9 0.016
III rs2227476 T 0.24 TT, TA 2.08 1.2–3.6 0.007
Table 2.  Association of IL22 SNPs with CM in the Nigerian population-based study. Severe cases were 
defined as children with cerebral malaria (CM, n = 115). The controls were community controls (CC, n = 160). 
aMAF (minor allele frequency) was estimated from Nigerian community control data. bAll the P-values 
reported are for two-tailed tests. OR, odds ratio; CI, confidence interval.
Bin SNP
Risk 
Allele Freqa Model
Informative 
families
Transmitted alleles
OR (95% CI) P- Valueb Pp-ValuecObserved Expected
II rs1012356 (A/T) T 0.49 ADD 168 177 163.3 1.46 (1.03–2.07) 0.06 0.06
III rs2227476 (A/T) T 0.23 REC 37 19 11.75 1.56 (1.09–2.17) 0.008 0.010
Table 3.  Association of IL22 SNPs with CM in the Malian family-based study. 240 trios (two parents and one 
child with CM) were included in the family-based association study. aFrequency of the risk allele in the Malian 
cohort. bTwo-tailed test relative to the risk allele (FBAT). cFBAT P-value obtained in the FBAT permutation test 
(100,000 permutations). OR, odds ratio; CI, confidence interval; ADD, additive; REC, recessive.
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Nigeria, and replication in a family-based population study in Mali. Two SNPs in the promoter region of IL22 
(rs2227476 and rs2227473) were associated with CM in both populations. The minor allele (the T allele) of these 
two SNPs increased the risk of CM in both populations. The rs2227473 SNP has been shown to influence suscep-
tibility to pulmonary tuberculosis in the Chinese population18 and the onset of psoriasis before puberty19. The 
rs2227473 and rs2227476 SNPs, which are in LD in Nigeria (r2 = 0.72) and Mali (r2 = 0.5), are probably located 
within transcription factor binding sites and may therefore have an effect on IL-22 production. Functional assays 
on PBMCs showed that cells with a homozygous TT genotype or a heterozygous TC genotype for rs2227473 pro-
duced more IL-22 than cells with a homozygous CC genotype for this SNP18. Luciferase reporter assays showed 
that transcription rates were higher for the T allele than for the C allele19. Ex vivo-stimulated CD4 T cells from 
psoriasis patients carrying the T allele at rs2227473 produced more IL-22 than stimulated cells from patients car-
rying the C allele19. Consistent with these findings, we found that rs2227473 was located within a putative binding 
site for the transcription factor AhR-ARNT complex, as also reported by Nikomo et al.19. The identified risk allele, 
the T allele, should confer a 30% higher AhR-ARNT complex binding efficiency19. The aryl-hydrocarbon receptor 
interacts with diverse ligands and acts as a master regulator of IL-22 production20–23. It is essential for IL-22 pro-
duction by Th17 cells24,25 and for Th17/Th22 polarization.
The rs2227473 variant may also alter putative binding sites for several transcription factors, including the 
Plasmodium falciparum PF14_0633, which has an AP2 domain26,27. This pathogen protein may target the host 
genes and regulate IL-22 expression18. These functional data and our genetic results suggest that the IL22 SNPs, 
rs2227476 and rs2227473 may be causal for cerebral malaria. They also show that the T allele of rs2227473, which 
is associated with greater susceptibility to CM, is also associated with higher levels of IL-22 production. These 
results suggest that IL-22 is associated with an aggravation of malaria.
This aggregation may occur in several ways. IL-22 may promote the breakdown of the blood- brain barrier. 
Recent results strongly suggest that Th17 cells play a unique role in permeabilizing the human BBB to both sol-
uble molecules and circulating CD4+ lymphocytes, through the action of IL-17 and IL-229. IL-22 may exert its 
pathogenic effects in CM by acting on endothelial cells to promote the disruption of the BBB observed during this 
disease3,28. This hypothesis is supported by the finding that the IL-22R is expressed on BBB endothelial cells and 
determines the responsiveness of these cells to IL-22. There is also in vivo evidence to suggest that IL-22 may act 
as a pathogenic effector in CM by increasing the ability of Th17 cells to enter the central nervous system (CNS). 
These Th17 cells may then produce multiple mediators, including cytolytic enzymes, such as granzyme B, strongly 
favoring the development of encephalitis.
Alternatively, IL-22 may be involved in neuroinflammation. In addition to regulating the expression of 
antimicrobial peptides and defensins, IL-22 plays a role in the expression of various genes encoding molecules 
involved in inflammation. IL-22 is necessary and sufficient to promote tissue inflammation in several models of 
inflammatory disorders at barrier surfaces. It can stimulate the release of TNF-α and IL-8 from epithelial cells29 
and may contribute to CM by enhancing inflammation in brain microvessels. The experimental autoimmune 
encephalomyelitis (EAE) model of multiple sclerosis (MS) is often used in studies of neuroinflammatory disease 
mechanisms. This model seems to have several features in common with CM. In vivo imaging in animals with 
experimental cerebral malaria has shown that the vascular damage observed, including BBB disruption, can be 
attributed to inflammatory processes30, as already reported for multiple sclerosis lesions. IL-22 levels increase 
during the induction of EAE and the peak of the disease, whereas a decrease in these levels is associated with 
recovery in the rat EAE model31.
The lack of association between CM and IL22RA2 polymorphisms suggests that IL-22BP may not regulate 
IL-22 production in CM. IL-22BP may not be produced at the site of IL-22 action. By contrast, IL-22 and other 
inflammatory cytokines, such as IL-17, are produced in sufficient amounts to increase disease severity9,32,33.
IL-22 has also been shown to have a deleterious effect in the pathogenesis of West Nile encephalitis, in which 
it may promote neuroinvasion by the virus16. High IL-17 and IL-22 levels have also been observed in the cerebro-
spinal fluid and plasma of patients developing Guillain-Barré Syndrome17, and are thought to cause disruption of 
the BBB and local inflammation of the peripheral nervous system.
Experimental blood-stage malarial infections have shown that IL-22 is probably protective in the liver. Indeed, 
protection from fatal liver tissue damage has been observed during primary Plasmodium chabaudi infection34, 
consistent with the known hepatoprotective function of IL-2212,35–37.
In conclusion, we have shown that variants of the IL22 gene may play an important role in the pathogenesis 
of CM and that these variants of IL22 are associated with an aggravation of malaria. The rs2227473 risk allele for 
CM, the T allele, is associated with higher levels of IL-22 production, suggesting that IL-22 contributes to CM. 
We suggest that IL-22, acting in synergy with IL-17A, may have a deleterious effect in cerebral malaria, through 
Bin SNP
Risk 
Allele Freqa Model Genotypes OR (95% CI) P Valueb
Univariate analysis
III rs2227476 (A/T)) T 0.24 ADD TT, TA 1.29 (1.04–1.73) 0.05
III rs2227473 (T/C) T 0.25 ADD TT, TC 1.46 (1.10–1.94) 0.008
Multivariate analysis III rs2227473 (T/C) T 0.25 ADD TT, TC 1.55 (1.15–2.07) 0.004
Table 4.  Association of IL22 SNPs with CM in the Nigerian and Malian cohorts. aFrequency of the risk allele 
in our study population. bTwo-tailed test relative to the risk allele. OR, odds ratio; CI, confidence interval; ADD, 
additive.
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the direct or indirect promotion of BBB permeability and brain inflammation, whilst protecting infected indi-
viduals against blood-stage infections and fatal liver tissue damage. It has been suggested that IL-22 acts as a 
gatekeeper, maintaining immune homeostasis at barrier surfaces through the induction of innate antimicrobial 
immunity6,13,38.
Materials and Methods
Ethics statement. The internationally recognized joint ethics committee of the College of Medicine of the 
University of Ibadan and the University College Hospital in Ibadan approved the Nigerian case-control study, 
which was part of a larger case-control study on severe malaria in children. The parents or guardians of chil-
dren from Ibadan, Nigeria gave written informed consent for the participation of their children in the study. 
Consent forms translated into Yoruba were provided where appropriate. The Malian study was performed with 
the approval of the local ethics committees of the Faculty of Medicine, Pharmacy and Odonto-Stomatology of the 
University of Bamako, and written informed consent was obtained from all parents. All experimental methods 
were carried out in accordance with the approved guidelines.
Study participants. We performed an association study for CM in two independent study populations from 
Africa: one cohort of children from the city of Ibadan, Nigeria and one cohort from Bamako, Mali.
All participating children from the city of Ibadan were recruited under the auspices of the Childhood Malaria 
Research Group (CMRG) of the Department of Pediatrics at University College Hospital (UCH), Ibadan, Nigeria. 
These children were part of a larger prospective case-control study of severe malaria described elsewhere39–41. 
Briefly, we recruited children between the ages of six months and 13 years with severe malaria defined according 
to WHO criteria42,43. Cerebral malaria (CM) was defined as a state of unarousable coma (Blantyre coma score ≤ 2) 
lasting for at least one hour, accompanied by parasitemia with asexual stages of Plasmodium falciparum and 
normal findings for cerebrospinal fluid. Children with CM were also considered to have severe malarial anemia 
(SMA) if they had a packed cell volume (PCV) of less than 16%. None of the recruited patients died. The commu-
nity control (CC) group consisted of age-matched parasite-negative children from the same community. These 
children had no patent symptoms of illness and were clinically healthy. The case-control study was performed on 
a population of 115 children with CM and 160 CCs. The mean age of the children with CM was 4.5 years (range: 
10 months - 13 years), and 47.8% of these patients were female. The CC children had a mean age of 6 years (range: 
6 months - 13 years), and 48.1% of these controls were female.
Malian children with CM were recruited through the Pediatrics Department of Gabriel Toure Hospital in 
Bamako, Mali. These hospitalized children were selected during a larger prospective study recruiting both chil-
dren with CM and SMA and their parents44–47. The criteria used to define CM were identical to those for the 
Nigerian study: coma with a Blantyre score ≤ 2 and a thick blood smear positive for P. falciparum. Meningitis was 
ruled out by lumbar puncture. A full description of the recruitment of Malian children is provided elsewhere45. In 
total, 240 nuclear families were recruited. The mean age of the children with CM was 6 years (range: 10 months to 
15 years), and 49.6% of these patients were female.
The basic characteristics of the two study populations have been described elsewhere48. Prospective subject 
selection allowed for careful phenotypic characterization and matching between the two populations.
Genomic DNA was extracted from the peripheral blood leukocytes of subjects from the Nigerian and Malian 
cohorts, as previously described45.
SNP selection and genotyping. Tagged SNPs were selected for the IL22 (MIM 605330) and IL22RA2 
(MIM 606648) genes, including 5 kb on either side of these genes. SNPs with a minor allele frequency ≥ 0.05 were 
selected from the 1000 Genomes YRI database, and PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/index.
shtml) was used to determine r2 values for correlations between SNPs. We selected one SNP per correlation bin, 
using an r2 cutoff of 0.8, and the singleton SNPs. This analysis resulted in the selection of 46 SNPs, 19 for IL22 
and 27 for IL22RA2. We genotyped these polymorphisms in the Nigerian population, which consisted of 115 
children with CM and 160 CCs, none of whom were related. Genotyping was performed with a custom-designed 
Sequenom IPLEX Assay, in accordance with the manufacturer’s instructions. SNPs were excluded if they had a 
call rate < 0.90 (Table 1).
The SNPs selected from these analyses (rs1012356 and rs2227476) were then genotyped in 240 nuclear fami-
lies from Mali. We also genotyped all the SNPs located within a 1 Mb window and in LD with rs2227476 (r2 > 0.6 
assessed by PLINK) according to the 1000 Genomes YRI database, in the Malian sample. In total, we geno-
typed 14 SNPs of IL22 or the surrounding regions (rs6581806 r2 = 0.82, rs11177141 r2 = 0.82, rs7954576 r2 = 0.82, 
rs4913430 r2 = 0.82, rs6581805 r2 = 0.82, rs4913429 r2 = 0.82, rs2127537 r2 = 0.82, rs7301738 r2 = 0.82, rs7298302 
r2 = 0.82, rs12307915 r2 = 0.82, rs2227481 r2 = 0.80, rs7298415 r2 = 0.72, rs2227478 r2 = 0.72 and rs2227473 
r2 = 0.69) in the Malian cohort, with either the IPLEX Assay (Sequenom) or TaqMan SNP Genotyping Assays 
(Applied Biosystems).
Statistical analysis. A Chi2 test was used to determine whether the genotype distribution in parents and 
controls conformed to Hardy-Weinberg equilibrium. None of the polymorphisms deviated from Hardy-Weinberg 
equilibrium in tests with a threshold for significance of P = 0.05 carried out in GenePop software.
Univariate and multivariate analyses of the SNPs were carried out with SPSS (statistical software version 20), to 
assess the association between the SNPs and CM in unrelated Nigerian subjects. Differences were considered to be 
significant if the P-value obtained in a two-tailed test was < 0.05. We first tested for associations between individual 
SNPs and the CM phenotype (univariate analysis) and we then analyzed the association between combinations of SNPs 
(associated or with a trend towards association with CM) and CM by logistic regression analysis (multivariate analysis).
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We used the family-based association test package (FBAT; version 1.7)49 for association tests in nuclear fam-
ilies from Mali. A SNP was considered to be replicated if the association analysis yielded a P-value < 0.05 in 
two-tailed tests, with the same risk allele as identified in the Nigerian population.
A case-pseudo control data set was used and a conditional logistic regression analysis was performed, as pre-
viously described47,50,51, to estimate the odds ratio (OR) in Malian subjects. We also performed a combined con-
ditional logistic regression analysis on both the discovery case-control cohort and the replication family-based 
cohort.
In silico analysis. We used the TFsearch program (http://www.cbrs.jp/research.db/TFSEARCH.html) to 
predict the potential transcription factor binding sites for IL22. We also used the RAVEN (regulatory analysis of 
variation in enhancers) system (http://www.cisreg.ca) to detect and characterize regulatory sequence variation52. 
This approach identifies genetic variants likely to influence gene regulation and combines phylogenetic footprint-
ing with the reported effects of genetic variation on putative transcription factor binding sites.
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